Ikonisys is a leading innovator in Fluorescence In Situ Hybridization (FISH) technology, specializing in advanced solutions for genetic analysis and cancer diagnostics. The company offers a range of automated systems designed to enhance the efficiency and accuracy of diagnostic testing. Their proprietary instruments, software applications, and reagents are protected by international patents, ensuring that their methodologies remain at the forefront of scientific research. Ikonisys's automated FISH cancer diagnostic solutions enable the screening of biological tissues for gene abnormalities, while their computer-controlled methods facilitate the detection of rare cell types in tissue samples. This integration of automation not only streamlines laboratory workflows but also minimizes human error, thereby improving the reliability of results.

In addition to their FISH technology, Ikonisys employs advanced imaging systems that combine high-speed capture and sensitivity, essential for detecting signals in biological samples. Their innovative approaches include computer automated image analysis and multiplexing techniques, which allow for the quantification of multiple fluorescent signals from cell samples. This versatility makes FISH an invaluable tool in oncology, aiding pathologists in diagnosing and monitoring cancer by providing critical insights into tumor biology and treatment responses. Overall, Ikonisys's commitment to automation, digitization, and quality assurance positions them as a key player in the evolving landscape of precision medicine and cancer diagnostics.

France

Ikonisys is a cell based diagnostics company, that markets the proprietary Ikoniscope® Digital Microscope, designed to deliver highly accurate and reliable detection of rare cells. Utilizing advanced molecular and immunological markers, Ikoniscope-built applications are extensively used in the US and Europe for the diagnosis of a variety of cancers.

Ikonisys

Company Details